
|Videos|June 1, 2021
Nevakar spins off ophthalmic-only company Vyluma
A new ophthalmic-only pharma company was formed when Nevakar spun off its pipeline of ocular drugs.
Advertisement
Navneet Puri, PhD, founder, chairman, and CEO of newly formed Vyluma discusses why Nevakar chose to make the move to ophthalmic-only pharma.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
South Korea's MFDS receives NDA for Tenpoint Therapeutics' Brimochol PF for presbyopia
2
Interventional glaucoma: Redefining the optometrist’s role in modern glaucoma management
3
Fitting the future: How technology is refining specialty lens care
4
Study examines association between air pollutants and dry eye via gene involvement
5


















































.png)


